Related Experiment Video
Updated: Jan 31, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Surfactant Administration in Preterm Infants: Drug Development Opportunities
Genevieve Taylor1, Wesley Jackson1, Christoph P Hornik2
1Department of Pediatrics, The University of North Carolina, Chapel Hill, NC.
Most surfactant use in preterm infants is off-label, particularly for those with higher birth weights or gestational ages. The increasing use of the INSURE method highlights a need for updated FDA labeling.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Pediatric Critical Care
Background:
- Surfactant therapy is crucial for respiratory distress syndrome in preterm infants.
- Current Food and Drug Administration (FDA) labeling may not reflect evolving clinical practices.
- Off-label use of medications is common in neonatology.
Purpose of the Study:
- To determine the frequency of off-label surfactant administration in preterm infants in the US.
- To analyze patterns of off-label surfactant use based on infant characteristics and administration methods.
Main Methods:
- Retrospective cohort analysis of administrative data from 348 US neonatal intensive care units (2005-2015).
- Quantified off-label use of poractant alfa, calfactant, and beractant in infants <37 weeks gestational age.
- Defined off-label use based on FDA labeling guidelines.
Main Results:
- 62% of 110,822 preterm infants receiving surfactant were administered it off-label.
- Off-label use was more common in infants with higher birth weight and older gestational age.
- The intubation and surfactant administration followed by immediate extubation (INSURE) method increased significantly from 2005-2015.
Conclusions:
- The majority of surfactant administration in preterm infants occurs off-label.
- Increased use of the INSURE technique aligns with growing evidence supporting its efficacy.
- The discrepancy between FDA labels and clinical practice suggests a need for label expansion, potentially requiring new safety and effectiveness data.
Related Concept Videos
Drug Dosing: Infants and Children
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Routes of Drug Administration: Enteral
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Routes of Drug Administration: Overview
Enteral administration refers to drugs absorbed through the gastrointestinal tract. They can be swallowed (perorally), placed under the tongue (sublingually), or on the inner lining of the cheeks (buccally). Perorally administered drugs take time to be absorbed and have a slower onset of action. The rectal route is another form of enteral administration, which allows for...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

